Conclusion: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. Finerenone caused 16% reduction in RR primary endpoint like cardiovascular deaths and worsening of heart failure. 12% reduction in rate ratio total number of worsening heart failure events. However, no significance difference in CV deaths was noted. Apparently, there was an increased risk of hyperkalemia and reduced risk of hypokalemia.